Next Generation Dx Summit

ADX_BDX_Track_Header

Companion Diagnostics is becoming a major source of revenue for diagnostics industry. However, it is facing an assemblage of challenges that require collaborative and synergetic work of all the stakeholders. Our Fifth Annual Companion Diagnostics: Strategy & Partnerships conference is designed to facilitate the knowledge and opinion exchange between pharmaceutical and diagnostics executives, translational scientists, clinicians, business experts, regulators, international companion diagnostics leaders, and other parties involved in drug-diagnostics co-development and precision medicine.


Day 1 | Day 2 | Short Courses | Download Brochure 


Recommended Pre-Conference Short Courses*

Regulatory Compliance in Drug Diagnostics Co-Development

Regulatory and Reimbursement Issues with NGS and Multiplex Assays


*Separate registration required


TUESDAY, AUGUST 19

7:30 am Main Conference Registration & Morning Coffee


KEYNOTE SESSION: CONVENING MAJOR STAKEHOLDERS

8:30 Chairperson’s Opening Remarks

Mitch Raponi, Clovis Oncology

8:40 15 Years of Personalized Medicine in Patient Care: Past, Present and Future

Eric LaiEric Lai, Ph.D., Senior Vice President & Head, Pharmacogenomics, Takeda Pharmaceuticals

Despite the complete sequencing of the Human Genome and the development of new molecular technologies, especially high-throughput DNA sequencing, the clinical application of personalized medicine is still limited. This presentation will discuss other potential ways of applying pharmacogenomics to drug development and the use of big research datasets to address unmet medical needs and patient stratification strategies for personalized medicine.

9:10 Challenges in Developing Companion Diagnostics with the Complexity of Cancer: Is NGS Assay a Solution?

J. Carl BarrettJ. Carl Barrett, Ph.D., Vice President, Translational Sciences, Onc iMed, AstraZeneca

Limitations of tissue and heterogeneity of cancers are both addressed by using NGS to interrogate cancers and select appropriate targeted therapies. Using NGS as a diagnostic however requires a better understanding of the challenges of NGS including target capture, sequencing platforms, variant calling and variant classification. The potential and pitfalls of NGS in clinical trials and diagnostic development will be discussed and illustrated.

9:40 Enabling Precision Medicine in the Age of Big Data

John QuackenbushJohn Quackenbush, Ph.D., Co-Founder and CEO, GenoSpace; Professor, Dana-Farber Cancer Institute and Harvard School of Public Health, Biostatistics and Computational Biology

Built on a secure, cloud-based infrastructure and using advanced analytical tools, GenoSpace has created a system enabling precision medicine application in research, in the practice of clinical medicine, and in support of patients and patient communities.

10:10 Coffee Break in the Exhibit Hall with Poster Viewing

10:55 Chairperson’s Remarks

11:00 International Case Study: Brazilian Strategy to Improve Access to Molecular Testing in Oncology - Building a Local Companion Diagnostics Platform

Carlos Gil FerreiraCarlos Gil Ferreira, M.D., Executive Director, INOVA-CANCER; Director, Clinical Research, Brazilian National Cancer Institute

In order to increase the access to high quality molecular testing in oncology, the Ministry of Health has launched a program that aims to develop the industry of companion diagnostics in the country. To that end partnerships between academia, pharma and diagnostic companies, regulatory agencies and government are being built.

11:30 HECON of Personalized Medicine

Nick Poulios, Ph.D., Head, MORE, Medical Outcomes: Reimbursement & Economics, Roche Molecular Systems, Inc.

This presentation will discuss health economics of personalized medicine in general and market access and reimbursement of companion diagnostics in particular.

12:00 pm Next-Generation Cancer Diagnostics at Illumina 

Frank_OngFrank S. Ong, M.D., Associate Director, Medical Affairs, Illumina, Inc.

Illumina provides a comprehensive line of products that address the scale and breadth of functional analysis required to achieve the goals of molecular medicine. From biomarker discovery to the development of MDx assays, our offering includes leading-edge solutions for NGS, genotyping, CNVs, GEx profiling, and DNA methylation. In this session we will provide an update on our clinical oncology strategy and discuss the work we are doing to position ourselves as a leading partner for the development of next gen cancer diagnostics.

12:30 Sponsored Presentation (Opportunity Available).

1:00 Luncheon Presentation I: Meeting the Clinical Utility Needs of Payers and Regulators for Molecular Diagnostics

David Parker, Ph.D., Vice President, Market Access Strategy, Precision for Medicine

Judi Smith, Vice President, In Vitro Diagnostics and Quality, Precision for Medicine

1:30 Luncheon Presentation II: (Sponsorship Opportunity Available)

2:00 Session Break


NEW PARTNERSHIP PARADIGM

2:15 Chairperson’s Remarks

Kevin M. Harter, Saladax Biomedical

2:20 Joint Presentation: Development of an NGS-Based Companion Diagnostic for the PARP Inhibitor Rucaparib

Mitch RaponiMitch Raponi, Senior Director, Molecular Diagnostics & Translational Medicine, Clovis Oncology





Matthew J. HawrylukMatthew J. Hawryluk, Ph.D., Senior Director, Corporate & Business Development, Foundation Medicine, Inc.

PARP inhibitors (PARPi) are active in patients (pts) with mutations in BRCA1/2, a critical component of homologous recombination repair (HRR). However, PARPi activity extends beyond BRCA, most likely in pts with tumors with other alterations leading to homologous recombination deficiency (HRD). Rucaparib, an oral PARPi, is being developed for treatment of relapsed, platinum-sensitive high grade serous ovarian cancer (HGSOC). A unique, integrated, translational-clinical program (Assessment of Rucaparib In ovarian cancEr triaLs (ARIEL)) is ongoing to identify HGSOC pts who may benefit from rucaparib treatment. In collaboration with Foundation Medicine, NGS of tumor tissue is being performed to identify somatic BRCA1/2 mutations as well as genomic defects caused by HRD that may be predictive of rucaparib response. The ARIEL trials are strategically aligned to allow for prospective clinical validation of a novel NGS-based companion diagnostic for rucaparib.

Affymetrix3:20 Sponsored Presentation 

Speaker to be Announced

3:50 Refreshment Break in the Exhibit Hall with Poster Viewing

4:30 Matching the Evolution of Diagnostic and Therapeutic Development: How Early is Early Enough?

Kevin M. HarterKevin M. Harter, President and CEO, Saladax Biomedical

The convergence of diagnostic and therapeutic development continues. Companion diagnostic development requires proper timing to avoid development and regulatory delays while also avoiding unnecessary costs during the process. This session will explore some critical time parameters in the co-development cycle and provide a framework for decision-making.

5:00 The Art of the Partnership - Claritas Genomics and Boston Children’s Hospital

Catherine BrownsteinCatherine Brownstein, M.D., Instructor, Pediatrics, Harvard Medical School and Boston Children’s Hospital

Offering clinical pharmacogenomics programs using state-of-the-art drug/gene knowledge is paramount to offering world-class patient care. In order to attain this goal, Boston Children’s has partnered with Life Technologies to create Claritas Genomics. BCH and Claritas are devoted advancing clinical pharmacogenomics to improve medication safety through precision medicine. There has been an explosion of interest in identifying and classifying genes with pharmacogenomic impact, and institutions, including at BCH, and our clinicians and researchers have been working towards incorporating this information into the medical record and clinical practice.

5:30 Wine and Cheese Pairing Welcome Reception in the Exhibit Hall with Poster Viewing 

6:30 Close of Day



Day 1 | Day 2 | Short Courses | Download Brochure